Insider Transactions in Q1 2021 at Nektar Therapeutics (NKTR)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 16
2021
|
Gil M Labrucherie SVP, COO & CFO |
SELL
Open market or private sale
|
Direct |
7,977
-2.99%
|
$175,494
$22.37 P/Share
|
|
Feb 16
2021
|
John Northcott SVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
15,358
-6.72%
|
$337,876
$22.37 P/Share
|
|
Feb 16
2021
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
11,495
-2.51%
|
$252,890
$22.37 P/Share
|
|
Feb 16
2021
|
Jillian B. Thomsen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11,705
-6.64%
|
$257,510
$22.37 P/Share
|
|
Feb 16
2021
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,173
-2.75%
|
$47,806
$22.37 P/Share
|
|
Feb 16
2021
|
Jonathan Zalevsky Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
24,141
-8.32%
|
$531,102
$22.37 P/Share
|
|
Feb 04
2021
|
Gil M Labrucherie SVP, COO & CFO |
SELL
Open market or private sale
|
Direct |
50,000
-15.77%
|
$950,000
$19.81 P/Share
|
|
Feb 04
2021
|
Gil M Labrucherie SVP, COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+13.63%
|
$400,000
$8.8 P/Share
|
|
Feb 04
2021
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
150,000
-13.17%
|
$3,000,000
$20.34 P/Share
|
|
Feb 04
2021
|
Howard W Robin President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
150,000
+19.77%
|
$1,200,000
$8.8 P/Share
|
|
Feb 03
2021
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,344
-6.34%
|
$101,536
$19.45 P/Share
|
|
Feb 03
2021
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Exercise of conversion of derivative security
|
Direct |
5,344
-5.97%
|
$42,752
$8.8 P/Share
|
|
Feb 03
2021
|
Gil M Labrucherie SVP, COO & CFO |
SELL
Open market or private sale
|
Direct |
50,000
-15.77%
|
$950,000
$19.61 P/Share
|
|
Feb 03
2021
|
Gil M Labrucherie SVP, COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+7.6%
|
$400,000
$8.8 P/Share
|
|
Feb 03
2021
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
150,000
-24.64%
|
$2,850,000
$19.72 P/Share
|
|
Feb 03
2021
|
Howard W Robin President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
150,000
+11.65%
|
$1,200,000
$8.8 P/Share
|
|
Feb 02
2021
|
Gil M Labrucherie SVP, COO & CFO |
SELL
Open market or private sale
|
Direct |
50,000
-5.4%
|
$1,000,000
$20.86 P/Share
|
|
Feb 02
2021
|
Gil M Labrucherie SVP, COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+13.63%
|
$400,000
$8.8 P/Share
|
|
Feb 02
2021
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
150,000
-8.39%
|
$3,000,000
$20.71 P/Share
|
|
Feb 02
2021
|
Howard W Robin President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
150,000
+19.77%
|
$1,200,000
$8.8 P/Share
|
|
Jan 28
2021
|
Jillian B. Thomsen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
75,000
-29.85%
|
$1,350,000
$18.62 P/Share
|
|
Jan 28
2021
|
Jillian B. Thomsen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
75,000
+13.96%
|
$600,000
$8.8 P/Share
|
|
Jan 05
2021
|
R Scott Greer Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+15.06%
|
$520,000
$13.8 P/Share
|